Forbion Capital Partners

What Forbion Capital Partners does

Forbion Capital Partners is a Netherlands-headquartered life sciences venture capital firm founded in 2006 that manages approximately €5 billion across 11 funds and operates from offices in Naarden, Munich, and Boston. The firm pursues two overarching strategies — Human Health and Planetary Health — delivered through four coordinated vehicles: Forbion Ventures (pre-clinical and early clinical biotech), Forbion Growth (private growth capital, crossover and public investments for clinical-stage drug development), Forbion BioEconomy (biotech applications in Food, Agriculture, Materials, and Environmental Technologies), and the Formation joint venture with BioGeneration Ventures (BGV) for seed and early-stage investments in the Benelux and Germany regions. Across these vehicles Forbion has made more than 130 portfolio investments spanning oncology, immunology, CNS, rare disease, cardiometabolic, ophthalmology, infectious disease, and climate/sustainability biotech, supported by a team of over 50 staff including 30-plus investment professionals and a roster of Operating Partners drawn from senior pharma R&D and corporate development roles.

Forbion's core capability is not a proprietary technology product but rather a repeatable company-building and capital-deployment engine: the firm sources, co-creates, and guides biotech companies through clinical and regulatory milestones, often leading or co-leading financing rounds ranging from small seed cheques to nine-figure Series B and C rounds. Recent portfolio activity includes lead or co-lead positions in financings such as Braveheart Bio ($185M Series A), CellCentric ($220M Series D), cAMPfield Therapeutics ($180M Series A), Coultreon Biopharma ($125M Series A), Tropic ($105M Series C), Sparrow Pharmaceuticals ($95M Series B), Altesa BioSciences ($75M Series B), Gate Bioscience ($65M Series B), and Mariana Oncology (acquired by Novartis for up to $1.75B). Beyond pure therapeutics the BioEconomy franchise targets technology-enabled biology in non-pharma verticals including phytomining (Genomines), gene-edited tropical crops (Tropic), textile recycling (Eeden), plant-based meats (Novameat), and biomaterials (PACT).

As a venture capital firm Forbion's revenue model is twofold: recurring management fees charged on assets under management across its fund vintages, plus performance-based carried interest realized on successful portfolio exits. The firm does not publicly disclose fee economics, but the €5B AUM base implies management fee revenue in the typical 1.5%–2% industry range, with carried interest contribution varying materially with exit timing. Capital is distributed exclusively through direct investment relationships, with limited partners being predominantly institutional investors such as pension funds, endowments, and fund-of-funds seeking life sciences venture exposure.

Name

Forbion Capital Partners

Legal name

FCPM III Services B.V.

Website

http://www.forbion.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Venture Capital Investment

NAICS

Other Financial Investment Activities (5239)

SIC

Finance Services (6199)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Venture capital firm
• Life sciences investment
• Biotech venture funding
• Pharmaceutical growth capital
• Planetary health investing

Headquarters

HQ city

Naarden

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Fund Management: Forbion generates revenue through management fees charged on assets under management across its multiple fund strategies, and through carried interest (performance fees) on successful portfolio company exits and realizations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Forbion Capital Partners is a Netherlands-based venture capital firm managing approximately €5 billion across 11 funds dedicated to advancing life sciences innovation. The firm deploys capital through multiple investment strategies covering all stages of biopharmaceutical drug development, from early-stage company formation through growth-stage investments. It also invests in planetary health solutions through its BioEconomy strategy across food, agriculture, materials, and environmental technologies.

Product overview

Forbion Capital Partners is a global life sciences venture capital firm managing approximately €5 billion across 11 funds. The firm operates three core investment strategies: Human Health (covering Ventures, Growth, and Formation through BGV joint venture) and Planetary Health (BioEconomy). Under Human Health, Forbion Ventures supports pre-clinical and early clinical biotech companies, Forbion Growth provides capital for clinical-stage drug development, and Formation targets seed/early-stage investments. The BioEconomy strategy invests in sustainable biotechnology solutions across Food, Agriculture, Materials, and Environmental Technologies. The portfolio includes companies such as cAMPfield Therapeutics (prifemilast for IBD), Elevara Medicines (ELV001 for rheumatoid arthritis), Coultreon Biopharma (COL-5671 for autoimmune diseases), Sparrow Pharmaceuticals (clofutriben for diabetes), Gate Bioscience (Molecular Gates), Altesa BioSciences (vapendavir for COPD), Vor Bio (telitacicept), Mariana Oncology (radiopharmaceuticals), Tropic (gene-edited crops), Genomines (phytomining), Novameat (plant-based meats), and PACT (biomaterials).

Differentiator

Problem solved

Functional benefit

Brands

• Forbion Ventures: Builds and supports pre-clinical and early clinical companies
• Forbion Growth
• Forbion BioEconomy

Products and services

• Forbion Ventures

Quantifiable outcome

• Multiple portfolio companies acquired for over $1 billion each within recent years
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• European Life Sciences Coalition (ELSC)coreStrategic or Co-development Partner · 16 April 2026Coalition launched with Invest Europe uniting major VC firms managing over €24 billion in life sciences assets. Members include Sofinnova Partners, Forbion, Novo Holdings, Omega Funds, HealthCap, and others. Aims to address structural funding gaps and mobilize capital for European biotech.
• BioGeneration Ventures (BGV)coreStrategic or Co-development PartnerJoint venture partnership for seed and early-stage investments in the Benelux and Germany regions. BGV together with its FIRST Fund is the early-stage strategy on Forbion's platform.
• Land LifeminorStrategic or Co-development PartnerPartnership for tree planting and carbon offset initiatives. Forbion has been supporting Land Life's Monarch Butterfly Reserve project in Mexico for the last four years to neutralize emissions from business operations.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sofinnova Partners: Paris-based European life sciences VC firm operating across early- and late-stage strategies. Direct peer to Forbion — both anchor large European biotech financings, frequently co-invest (e.g., Coultreon, Elevara), and share similar multi-stage platform and European biotech mandate.
• Atlas Venture: Boston-based early-stage life sciences VC firm building biotech companies from inception. Direct peer to Forbion Ventures — both focus on company creation, seed/Series A biotech, and frequently co-lead rounds (e.g., Mariana Oncology, AAVantgarde).
• RA Capital Management: Boston-based healthcare-focused investment firm with crossover, public, and private funds. Direct peer — frequently co-leads clinical-stage rounds with Forbion (e.g., Sparrow, Slate, Braveheart) and competes for late-stage biotech allocations.
• Novo Holdings: Denmark-based holding company of the Novo Nordisk Foundation with major life sciences VC operations. Direct peer to Forbion — both European-anchored, leading biotech financings (Coultreon) and aligned via historical ties to Novo Nordisk pharma relationships.
• EQT Life Sciences: European life sciences VC arm of EQT, formerly LSP. Direct peer — similar multi-stage mandate, frequently co-invests (e.g., Mosanna, cAMPfield via Frazier), and operates across European biotech and medtech verticals.
• HealthCap: Nordic-European healthcare VC firm investing across biotech and medtech. Direct peer to Forbion — similar European base, late-stage clinical focus, and ELSC coalition co-member addressing European biotech funding gaps.
• Versant Ventures: US- and Canadian-based healthcare VC firm with operations in biotech, medtech, and healthcare services. Direct peer — invests across similar stages and modalities, frequently co-invests (e.g., Gate Bioscience) and competes for clinical-stage biotech deals.
• Frazier Life Sciences: US-based life sciences investment firm focused on biopharma across public and private markets. Direct peer — co-leads clinical-stage rounds with Forbion (cAMPfield, RQ Bio) and competes for late-stage biotech allocations.

Broad incumbents

• OrbiMed: Global healthcare-dedicated investment firm with multi-strategy funds across venture, growth, and public equity. Broad incumbent peer — overlaps with Forbion across venture and growth stages (e.g., Braveheart, Sparrow) but operates at much larger AUM and broader scope.

Emerging players

• BioGeneration Ventures (BGV): Dutch early-stage life sciences VC firm operating as Forbion's joint venture partner. Emerging-player peer — comparable in early-stage biotech mandate but smaller AUM and tightly integrated with Forbion's Formation strategy in Benelux and Germany.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCDg4iyZm6YUYfd5eO4F74ZA
• LinkedInlinkedin.com/company/forbion-capital-partners
• Xx.com/forbionlifesci

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments197 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forbion Capital Partners